Drug Profile
INGN 241
Alternative Names: Ad-mda7; Adenoviral-mda7 - Introgen; Mda 7 gene therapy - IntrogenLatest Information Update: 02 Aug 2023
Price :
$50
*
At a glance
- Originator Columbia University
- Developer Introgen Therapeutics
- Class Antineoplastics; Gene therapies
- Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; Immunostimulants; NF-kappa B inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Breast cancer; Head and neck cancer; Lung cancer; Malignant melanoma; Pancreatic cancer; Solid tumours
Most Recent Events
- 05 Nov 2009 Discontinued - Phase-I/II for Solid tumours in USA (Intratumoural)
- 05 Nov 2009 Discontinued - Phase-II for Malignant melanoma in USA (Intratumoural)
- 05 Nov 2009 Discontinued - Phase-III for Head and neck cancer in USA (Intratumoural)